Complix
- Company typePrivate
- Founded2008
- HeadquartersDiepenbeek, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingServices
Complix firmographics
Firmographics- Name
- Complix
- Legal name
- Complix N.V.
- Website
- https://complix.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Complix industry classification
Industry- Product category
- Biopharmaceutical Drug Discovery and Development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Complix is headquartered
LocationHeadquarters
- HQ city
- Diepenbeek
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
Complix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership Milestone Payments: Complix receives upfront payments and potential development and regulatory milestone payments from pharmaceutical partners. The MSD collaboration is worth up to $280 million in upfront and milestone payments, plus tiered mid-single digit royalties on global sales.
- Research Funding: Partners such as MSD fund research activities related to CPAB development programs.
- Royalty Payments: Complix is eligible to receive tiered royalties based on future commercial sales of developed therapeutics in licensed territories.
- Grant Funding: Complix receives government grants for research programs, such as the €1.2 million VLAIO grant for anti-Covid-19 Alphabody development and €0.5 million VLAIO grant for nuclear targeting CPABs.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Complix product offering
Product offeringCore offering
Complix develops Cell Penetrating Alphabodies (CPABs), a proprietary class of biopharmaceuticals that combine the specificity of antibodies with the cell-penetrating capacity of small molecules. The company's pipeline targets intracellular disease mediators — primarily in oncology, immuno-oncology, autoimmune disease, CNS disease, and viral infections — that are considered intractable by conventional antibody or small-molecule drug formats. CPABs are licensed and co-developed with major pharmaceutical partners through upfront payments, milestone payments, and royalties.
Product overview
Complix is a biopharmaceutical company built around its proprietary Alphabody platform, which generates Cell Penetrating Alphabodies (CPABs) — a novel class of biotherapeutics that combine the high specificity of antibodies with the cell-penetrating ability of small molecules. The platform enables access to intracellular targets in the cytosol and nucleus that are considered 'undruggable' by conventional drug formats. The company's pipeline includes CMX-02 (a bispecific Alphabody-antibody fusion targeting TNFα and IL-23 for autoimmune disease), anti-MCL-1 CPABs for oncology, and Covid-19 Alphabody therapeutics. Complix is also engaged in partnered programs with MSD (Merck), I-Mab, and Jiangsu Nhwa for oncology, immuno-oncology, and CNS disease applications.
Differentiator
Problem solved
Functional benefit
Brands
- Alphabody: Complix's proprietary platform technology for developing transformative biotherapeutics that can penetrate cells and address intracellular targets.
- Cell Penetrating Alphabodies (CPAB)
- CMX-02
Products and services
- Cell Penetrating Alphabodies (CPABs) Platform Proprietary class of biotherapeutics combining the specificity of antibodies with the cell-penetrating capacity of small molecules; enables access to intracellular targets in the cytosol and nucleus that are considered undruggable by conventional drug formats. Offered to pharmaceutical partners through licensing and co-development.
- CMX-02 (Bispecific TNFα/IL-23 Alphabody-Antibody Fusion) Bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23 cytokines for the treatment of severe autoimmune diseases (e.g., psoriatic arthritis, Crohn's disease). Being developed using the Selexis SUREtechnology Platform for manufacturing.
- Anti-MCL-1 CPABs Cell Penetrating Alphabodies targeting the intracellular cancer target MCL-1, an apoptosis regulator implicated in multiple hematological cancers; part of Complix's oncology pipeline developed under the MSD collaboration.
- CMX-01 (Oncology CPAB Therapeutic) Cell Penetrating Alphabody therapeutic candidate targeting intracellular oncogenic drivers for cancer treatment under the MSD collaboration.
- Anti-Coronavirus Alphabody Therapeutics Anti-coronavirus Alphabody therapeutics targeting highly conserved viral fusion machinery for both prophylactic and therapeutic efficacy against SARS-CoV-2 and future coronavirus variants.
- MSD Cancer CPAB Collaboration (Up to $280M) Strategic co-development and licensing agreement with MSD worth up to US$280M for the development of CPABs against intracellular cancer targets; MSD funds research and holds option to exclusive worldwide rights.
- I-Mab Immuno-Oncology CPAB Collaboration Global drug discovery agreement with I-Mab to develop CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China; I-Mab holds exclusive Greater China commercialization rights.
- Jiangsu Nhwa CNS Disease CPAB Collaboration Global collaboration with Jiangsu Nhwa Pharmaceutical Co. to develop CPABs that cross the blood-brain barrier for CNS diseases; exclusive Greater China license to Nhwa, with joint development and commercialization rights for the rest of the world.
Quantifiable outcome
- CPABs can remain stable within tumor tissue for up to 24 hours post administration
- +2 more outcomes
Companies that use Complix
Customer profileSegments5 records
Ideal customer profiles1 record
Complix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Complix partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Jiangsu Nhwa Pharmaceutical Co.coreGlobal collaboration and license agreement to develop CPABs able to cross the blood-brain barrier for CNS diseases. Complix granted exclusive license to Nhwa for Greater China development, manufacturing, and commercialization. Both companies retain joint development and commercialization rights for rest of world. Complix entitled to upfront license payments, milestone payments, and royalty payments on commercial sales in China.
- VIB (Vlaams Instituut voor Biotechnologie)coreJoint multidisciplinary research collaboration with VIB and Ghent University resulting in publication in Science Advances. Study demonstrates CPABs efficiently penetrate cancer cell membranes, disrupt intracellular protein-protein interfaces, and cause anti-tumor effects in vivo. Prof Savvas Savvides leads VIB team at Center for Inflammation Research.
- I-MabcoreGlobal drug discovery and development agreement for CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China. I-Mab has exclusive license to commercialize in Greater China. Complix receives upfront fees, research funding, and potential milestone and royalty payments.
- Prof Savvas Savvides (VIB-UGent Center for Inflammation Research)minorResearch collaboration on anti-viral Alphabody program focusing on 3D-structure determination of Alphabody-viral protein complexes.
- Prof Johan Neyts (Rega Institute for Medical Research, KU Leuven)minorResearch collaboration on anti-viral Alphabody program for functional characterization of anti-viral compounds.
- MSD (Merck & Co., Inc.)coreStrategic drug discovery collaboration to develop Cell Penetrating Alphabodies for cancer treatment. Complix uses its Alphabody platform to deliver CPABs against up to two intracellular cancer targets. MSD funds research and has option to exclusive worldwide rights. Complix entitled to upfront payment and potential development milestones up to $280 million plus tiered royalties. Collaboration expanded in July 2017 when MSD exercised option on second target program.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Complix competitors and assessment
Company assessmentEmerging players
- Foghorn Therapeutics: Foghorn develops medicines that target chromatin regulatory machinery, including previously undruggable intracellular cancer targets. Its focus on intracellular oncology biology overlaps with Complix's intracellular cancer target thesis, particularly around transcription factors and regulatory proteins.
- Harpoon Therapeutics: Harpoon develops engineered T-cell engagers (TriTACs) and other targeted protein-based immunotherapies for oncology. It shares Complix's approach of using proprietary protein engineering to address cancer targets with novel binding modalities.
- CytomX Therapeutics: CytomX's Probody platform engineers conditionally activated antibody therapeutics, including for intracellular targets via masking strategies. It overlaps with Complix in the pursuit of protein-based therapeutics aimed at challenging oncology targets beyond conventional antibody reach.
- Arvinas: Arvinas is the pioneer of PROTAC targeted protein degraders, leveraging bifunctional small molecules to address intracellular disease-driving proteins. Like Complix, Arvinas pursues intracellular oncology targets that have historically been considered undruggable.
- Crinetics Pharmaceuticals: Crinetics develops oral peptide therapeutics targeting G-protein-coupled receptors and other challenging endocrine and oncology targets. It shares Complix's emphasis on non-injectable routes of administration and tackling disease targets that conventional biologics cannot reach.
- Nurix Therapeutics: Nurix develops targeted protein degradation drugs (PROTACs and molecular glues) that hijack the cell's ubiquitin-proteasome system to eliminate disease-driving proteins, including intracellular targets such as transcription factors. Like Complix, Nurix pursues intracellular oncology targets that conventional drugs cannot address.
Direct peers
- Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptides, a constrained peptide scaffold similar in concept to Complix's alpha-helical Alphabodies, with the goal of addressing intracellular and traditionally hard-to-drug targets in oncology. Both companies use small, computationally designed protein/peptide scaffolds to reach targets outside the reach of conventional antibodies.
- Affibody: Affibody develops small protein scaffolds (affibody molecules) for therapeutic applications including oncology and autoimmune disease. Like Complix's Alphabodies, affibody molecules are rationally designed, small protein-based binders intended to access targets that traditional antibodies struggle to address.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron operates one of the largest protein-based therapeutic platforms, including antibody and bispecific approaches addressing oncology and autoimmune disease. It is comparable to Complix as a benchmark for how protein-engineering platforms can scale into multi-billion-dollar franchises.
- Ablynx (Sanofi): Ablynx (acquired by Sanofi) pioneered Nanobodies, small single-domain antibody fragments, and was co-founded by Complix CEO Mark Vaeck. It represents the broader small-protein-therapeutic precedent most directly relevant to Complix's Alphabody platform and serves as a benchmark for the asset class's commercial potential.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Complix social profiles
Digital presenceComplix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Complix leadership team
Management profileNumber of profiles
Profiles6 records
Complix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Complix funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Complix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Complix
What does Complix do?
Complix develops Cell Penetrating Alphabodies (CPABs), a proprietary class of biopharmaceuticals that combine the specificity of antibodies with the cell-penetrating capacity of small molecules. The company's pipeline targets intracellular disease mediators — primarily in oncology, immuno-oncology, autoimmune disease, CNS disease, and viral infections — that are considered intractable by conventional antibody or small-molecule drug formats. CPABs are licensed and co-developed with major pharmaceutical partners through upfront payments, milestone payments, and royalties.
Is Complix a public or private company?
Complix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Complix founded?
Complix was founded in 2008. It employs 11 to 50 people.
Where is Complix based?
Complix is headquartered in Diepenbeek, Belgium, in the Europe region.
How does Complix make money?
Four revenue lines are on record. Partnership Milestone Payments are the primary driver. The others are research Funding, royalty Payments and grant Funding.
Who are Complix's main competitors?
Emerging players on record are Foghorn Therapeutics, Harpoon Therapeutics, CytomX Therapeutics, Arvinas, Crinetics Pharmaceuticals and Nurix Therapeutics. Direct peers are Bicycle Therapeutics and Affibody. Broad incumbents are Regeneron Pharmaceuticals and Ablynx (Sanofi).
Does Complix have an API?
No public API is recorded for Complix.
What industry is Complix in?
Complix's product category is Biopharmaceutical Drug Discovery and Development. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.